Browsing Tag
Orna Therapeutics
3 posts
Lilly (NYSE: LLY) to acquire Orna Therapeutics for $2.4bn to expand in vivo CAR-T strategy
Eli Lilly and Company (LLY) to acquire Orna Therapeutics for up to $2.4B. Explore how in vivo CAR-T and circular RNA may transform autoimmune therapy.
The in-vivo revolution: How pharma is racing to reprogram immunity inside the body
Explore how pharma giants like Bristol Myers Squibb are driving the in-vivo revolution to reprogram immunity and transform autoimmune and cancer care.
Orna Therapeutics acquires ReNAgade Therapeutics, appoints new CEO to lead RNA therapeutics innovation
Orna Therapeutics, a pioneer in the field of circular RNA therapeutics, has officially announced its acquisition of ReNAgade…